SEMAGLUTIN AND LIRAGLUTIDE IN THE TREATMENT OF OBESITY
DOI:
https://doi.org/10.63330/armv1n7-004Keywords:
Semaglutide, Liraglutide, Obesity, Glycopeptide-1 receptor agonistsAbstract
Obesity, a global public health challenge, demands innovative strategies. This study investigated the use of semaglutide and liraglutide, GLP-1 receptor agonists, for treating obesity. The research employed a mixed-methods approach, integrating qualitative and quantitative methodologies through a literature review, with an emphasis on the period from 2018 to 2023. Strict inclusion and exclusion criteria were applied to ensure study quality, with research conducted in reliable databases such as PubMed and Scopus, using specific keywords in English and Portuguese.The results revealed the efficacy of these agonists in reducing body mass index and improving metabolic parameters in obese patients. However, ethical and regulatory challenges associated with the often off-label prescription of this class of drugs were identified, highlighting the need for a careful approach. The study analysis emphasized potential side effects and risks, necessitating thorough clinical evaluation.Ethical clinical practice underscored the importance of treatment individualization, psychosocial support, and transparency in communication. In conclusion, the use of semaglutide and liraglutide in obesity management is a promising yet challenging approach. Further studies on individual responses, long-term safety, and comparisons with other treatments are necessary. The integration of these medications into clinical practice requires an ethical, scientific approach aligned with current regulations. Optimizing their therapeutic potential demands a continuous pursuit of evidence, ethical considerations in prescribing, and attention to regulatory issues.
References
Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E., ... & Rissanen, A. (2012). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International journal of obesity, 36(6), 843-854.
Bray, G. A., Kim, K. K., & Wilding, J. P. H. (2018). Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews, 18(7), 715-723.
Costa, P. et al. (2021). "Considerations on the Economic Viability of Off-Label Use of Semaglutide and Liraglutida for Obesity." Journal of Health Economics, 28(4), 567-580.
Encosta, A. et al. (2021). "Políticas de Acesso a Tratamentos Inovadores na Obesidade". Revista de Saúde Pública, v. 20, n. 3, p. 123-135.
Encosta, G., Santos, H. Equidade na distribuição de tratamentos inovadores para obesidade: uma abordagem econômica. Revista de Economia em Saúde, v. 2, n. 4, p. 200-215, 2017.
Food and Drug Administration [FDA]. (2022). "Off-Label Use of FDA-Approved Drugs." Retrieved from https://www.fda.gov/patients/learn-about-expanded-access-and-other- treatment-options/off-label-use-fda-approved-drugs
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2019). The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health, 9(1), 88.
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., ... & Pi- Sunyer, X. (2020). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet, 394(10193), 121-130.
Lima, A. et al. (2022). "Efficacy and Safety of Off-Label Use of Semaglutide and Liraglutida for Obesity: A Systematic Review." Journal of Obesity Research, 15(3), 123-136.
Lixa, C., Costa, D. Revisão sistemática sobre a eficácia de agonistas GLP-1 no tratamento da obesidade. Journal of Obesity Research, v. 5, n. 3, p. 100-115, 2020.
National Institute for Health and Care Excellence [NICE]. (2014). Obesity: Identification, Assessment and Management. Retrieved from https://www.nice.org.uk/guidance/cg189
Oliveira, F. Segurança a longo prazo do uso off-label de medicamentos para diabetes no tratamento da obesidade. Farmacovigilância em Foco, v. 3, n. 2, p. 50-65, 2018.
Oliveira, M. (2021). "Off-Label Use of Medications: Ethical Considerations in Clinical Practice." Journal of Medical Ethics, 28(2), 215-230.
Pereira, E. Considerações éticas no uso off-label de semaglutina e liraglutida. Ética em Saúde, v. 7, n. 1, p. 300-315, 2019.
Pereira, J. (2018). "Ética na Prescrição Off-Label de Medicamentos." Revista de Ética Médica, v. 7, n. 1, p. 78-92.
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Scheen,
A. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
Santos, A., Silva, B. Uso off-label de semaglutina e liraglutida no tratamento da obesidade: mecanismos de ação e implicações clínicas. Revista de Medicina, v. 10, n. 2, p. 150-165, 2021.
Santos, C., Lima, A., & Silva, J. (2020). Central mechanisms of action of Semaglutide and Liraglutide in obesity: Evidence from preclinical studies. Obesity Reviews, 21(9), e13030.
Santos, M. et al. (2020). "Avaliação da Resposta Individual ao Uso de Semaglutina e Liraglutida na Obesidade." Journal of Obesity Research, v. 25, n. 4, p. 210-225.
World Health Organization [WHO]. (2020). "Rational Use of Medicines." Retrieved from https://www.who.int/campaigns/world-antibiotic-awareness-week/waw-2019/ib-2019/who- rational-use-antibiotics-factsheet-2019.pdf
NASCIMENTO, F.; FERNANDES, A.; BARBOSA, J. “Liraglutida comparada a terapia padrão para o tratamento da obesidade”. Revista da Escola de Saúde Pública, v. 8, n. 1, p. 1- 15, 2022.
NASCIMENTO, J. C., LIMA, W. M. G.,TREVISAN, M. A atuação do farmacêutico no uso da Semaglutida (Ozempic): uma revisão integrativa. Brazilian Journal of Development, 7(11). 10.34117/bjdv7n11-498, 2021.
GOMES, H. K. B. C.; TREVISAN, M. O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos. Com,
v. 29, p. e7498. 2021. Disponível em: https://acervomais.com.br/index.php/artigos/article/view/7498#:~:text=Resultados%3 A%20A%20revis%C3%A3o%20refere%2Dse,perda%20e%20manuten%C3%A7%C 3%A3o%20do%20peso.
WILDING, J. P. H. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. vol 384. n 11. 2021. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183.
BRASIL. Lei 8.080 de 19 de setembro de 1990. Lei Orgânica da Saúde. Brasília, 19 set. 1990.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Hermínio Oliveira Medeiros, Rogerson Bastos Bello de Oliveira, Gabriel Junior Pimentel (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
